Denis Z. T.
- Country
- Spain
- Department
- Hematology
Research Overview
- Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Budoprutug (TNT119) in Patients with Immune Thrombocytopenia
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia
- Long-term Safety and Efficacy Evaluation of Mezagitamab in Adults with Chronic Primary Immune Thrombocytopenia: A Phase 3 Open-label Multicenter Continuation Trial
Data & Insights
Has run more than one trial at 45 of 52 partner sites.
Specializations
Hematologic malignancies
The investigator is involved in clinical research across a broad range of blood cancers, including acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, and non-Hodgkin lymphoma. The portfolio also includes myelodysplastic syndromes, myelofibrosis, and other relapsed or refractory hematologic disorders.
- Acute myeloid leukemia
- Chronic lymphocytic leukemia
- Multiple myeloma
- Diffuse large B-cell lymphoma
Research activity in this area also extends to graft-versus-host disease and post-transplant hematologic care.
Thoracic and solid tumor oncology
Clinical work includes advanced malignancies of the lung, with emphasis on non-small cell lung cancer, small cell lung cancer, and molecularly selected thoracic tumors. The investigator is also engaged in trials for head and neck squamous cell carcinoma, melanoma, and mesothelioma.
- Non-small cell lung cancer
- Small cell lung cancer
- Head and neck squamous cell carcinoma
- Melanoma
The solid tumor portfolio also covers biomarker-driven oncology, including EGFR-altered and ALK-rearranged disease.
Genitourinary and prostate cancer
The investigator’s research landscape includes urothelial carcinoma, renal cell carcinoma, and multiple settings of prostate cancer, ranging from hormone-sensitive disease to metastatic castration-resistant prostate cancer. Studies also address bladder tumors across non-muscle invasive and muscle-invasive settings.
- Urothelial carcinoma
- Renal cell carcinoma
- Metastatic castration-resistant prostate cancer
- Muscle-invasive bladder cancer
Interest in this domain includes advanced disease management and genomically defined genitourinary tumors.
Breast, gynecologic, and gastrointestinal cancers
Research activity spans breast cancer subtypes such as HER2-positive breast cancer, hormone receptor-positive breast cancer, and triple-negative breast cancer, alongside ovarian cancer, endometrial cancer, cervical cancer, cholangiocarcinoma, gastric cancer, and colorectal cancer.
- Breast cancer
- Ovarian cancer
- Endometrial cancer
- Colorectal cancer
This area reflects involvement in biomarker-informed treatment strategies for advanced solid tumors across digestive and gynecologic oncology.
Immune-mediated and rare diseases
The investigator is also active in non-oncologic therapeutic areas, including psoriatic arthritis, ulcerative colitis, Crohn’s disease, systemic lupus erythematosus, bullous pemphigoid, and primary biliary cholangitis. Additional interest is seen in rare and complex conditions such as AL amyloidosis, Niemann-Pick disease type C1, and cystic fibrosis.
- Psoriatic arthritis
- Inflammatory bowel disease
- Systemic lupus erythematosus
- Rare metabolic and lysosomal disorders
These studies connect immune modulation, inflammatory disease control, and rare-disease therapeutic development.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.